Biotransformation of irbesartan in man

Drug Metabolism and Disposition

Volumn 26, Issue 5, 1998, Pages 408-417

  Chando, Theodore J ^b   Everett, Donald W ^a   Kahle, Alicia D ^b   Starrett, Anne M ^b   Vachharajani, Nimish ^b   Shyu, Wen Chyi ^b   Kripalani, Kishin J ^b   Barbhaiya, Rashmi H ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IRBESARTAN;

ARTICLE; BIOTRANSFORMATION; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOACTIVITY;

ANTIHYPERTENSIVE AGENTS; BIOTRANSFORMATION; BIPHENYL COMPOUNDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MALE; REFERENCE VALUES; TETRAZOLES;

EID: 0031902451     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 265:826-834.
2. Eberhardt RT, Kevak RM, Kang PM and Frishman WH (1993) Angiotensin II receptor blockade: An innovative approach to cardiovascular pharmacotherapy. J Clin Pharmacol 33:1023-1038.
3. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T and DeKock M (1993) Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88:1602-1609.
4. Huskey S-EW, Miller RR and Chiu S-HL (1993) I. N-Glucuronidation reactions: Terazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans. Drug Metab Dispos 21:792-799.
5. Kondo T, Yoshida K, Yoshimura Y, Motohashi M and Tanayama S (1996) Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectroscopy following chemical derivatization. J Mass Spectrom 31:873-878.
6. Lacourcière Y, Brunner H, Irwin R, Karlberg BE, Ramsay LE, Snavely DB, Dobbins TW, Faison EP and Nelson EB (1994) Effects of modulators of the renin-angiotensin-aldosterone system on cough: Losartan cough study group. J Hypertens 12:1387-1393.
7. Necciari J, Denolle T, Le Coz F, Donazollo Y, Pastor G and Sissmann J (1994) Pharmacokinetics of SR 47436 (BMS-186295), a new angiotensin II receptor antagonist in man. J Hypertens 12:88.
8. Perrier L, Bourrie M, Marti E, Tronquet C, Masse D, Berger Y, Magdalou J and Fabre G (1994) In vitro N-glucuronidation of SR 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J Pharmacol Exp Ther 271:91-99.
9. Stearns RA, Doss GA, Miller RR and Chiu S-HL (1991) Synthesis and identification of a novel tetrazole metabolite of the angiotensin II receptor antagonist DuP 753. Drug Metab Dispos 19:1160-1162.
10. Stearns RA, Miller RR, Doss GA, Chakravarty PK, Rosegay A, Gatto GJ and Chiu S-HL (1992) The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab Dispos 20:281-287.
11. Tronquet C, Mandray M, Masse D, Miscoria G and Berger Y (1996) Excretion and metabolism following single oral administration (10 mg/kg) of irbesartan to Macaca fascicularis monkeys. Abstract presented at the Seventh American ISSX Meeting, San Diego, CA, 1996. ISSX Proceedings 10:321.
12. Vachharajani N, Chang SY, Shyu WC., Greene D and Barbhaiya R (1995) Absolute bioavailability of irbesartan, an angiotensin II receptor antagonist, in man. Pharm Res 12:S-388.
13. 1 receptor antagonist irbesartan in hypertension. Hypertension 25:22-29.